Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition Post published:November 26, 2025 Post category:Interviews/Pα+
Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action Post published:November 13, 2025 Post category:Interviews
A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda Post published:October 22, 2025 Post category:Interviews
Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall Post published:October 14, 2025 Post category:Interviews/Pα+
‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance Post published:September 11, 2025 Post category:Interviews/Pα+
From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research Post published:August 12, 2025 Post category:Analysis/Interviews
Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches Post published:August 5, 2025 Post category:Analysis/Interviews/News/Pα+
From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook Post published:July 7, 2025 Post category:Interviews/Pα+
Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics Post published:July 3, 2025 Post category:Interviews
Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans Post published:July 1, 2025 Post category:Interviews/Pα+